Foundation Medicine Inc (NASDAQ:FMI) insider Vincent A. Miller sold 20,000 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $61.17, for a total value of $1,223,400.00. Following the sale, the insider now owns 99,984 shares in the company, valued at $6,116,021.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Foundation Medicine Inc (FMI) traded down $0.60 on Thursday, hitting $58.30. The stock had a trading volume of 306,400 shares, compared to its average volume of 232,342. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. Foundation Medicine Inc has a 1-year low of $17.10 and a 1-year high of $70.75.
Foundation Medicine (NASDAQ:FMI) last issued its earnings results on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The business had revenue of $42.66 million during the quarter, compared to analysts’ expectations of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. Foundation Medicine’s revenue was up 45.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.90) earnings per share. equities research analysts forecast that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.
FMI has been the topic of a number of research reports. Zacks Investment Research cut Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. BidaskClub upgraded Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $45.33.
Several large investors have recently made changes to their positions in FMI. Legal & General Group Plc raised its holdings in Foundation Medicine by 8.6% during the second quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock valued at $138,000 after buying an additional 274 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Foundation Medicine by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,747 shares of the company’s stock valued at $467,000 after purchasing an additional 341 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Foundation Medicine by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock valued at $2,449,000 after purchasing an additional 835 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Foundation Medicine by 8.8% in the second quarter. Wells Fargo & Company MN now owns 11,510 shares of the company’s stock valued at $458,000 after purchasing an additional 931 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Foundation Medicine by 5.7% in the first quarter. Teachers Advisors LLC now owns 24,387 shares of the company’s stock valued at $786,000 after purchasing an additional 1,316 shares during the last quarter. Institutional investors and hedge funds own 33.44% of the company’s stock.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.